Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 12, 2007, Pages 1434-1439

  Fabris, Martina ^a   Visentini, Daniela ^b   De Re, Valli ^c   Picierno, Alessia ^b   Maieron, Roberto ^b   Cannizzaro, Renato ^c   Villalta, Danilo ^d   Curcio, Francesco ^a   De Vita, Salvatore ^a   Tonutti, Elio ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d Pordenone Hospital   (Italy)

Author keywords

Anti transglutaminase antibodies; Autoimmunity; B cells; BAFF BlyS; Coeliac disease; Lymphoma

Indexed keywords

B CELL ACTIVATING FACTOR OF THE TUMOR NECROSIS FACTOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD DONOR; CELIAC DISEASE; CELL SURVIVAL; CHILD; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GLUTEN FREE DIET; HUMAN; IMMUNOFLUORESCENCE; IMMUNOLOGICAL TOLERANCE; INTESTINE BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; CELIAC DISEASE; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INFANT; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 36248929907     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701452225     Document Type: Article

References (43)

1. Mackay F, Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol 2002;23:113-5.
2. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
3. Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep 2002;4:345-50.
4. Seyler TM, Park YW, Takemura S, Bram RJ, Kurtin PJ, Goronzy JJ, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005;115(11):3083-92.
5. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71.
6. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S, et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006;54:192-201.
7. Fabris M, Quartuccio L, Sacco S, de Marchi D, Pozzato G, Mazzaro C, et al. B-lymphocyte stimulator (BLyS) upregulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 2007;46:37-43.
8. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001;97:198-204.
9. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1453-66.
10. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-9.
11. Sutherland AP, Ng LG, Fletcher CA, Shum B, Newton RA, Grey ST, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005;174:5537-44.
12. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174:864-70.
13. Krumbholz M, Theil D, Derfuss T, Rosenala A, Schrader F, Monoranu CM, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;201:195-200.
14. Ittah M, Miceli-Richard C, Eric Gottenberg J, lavie F, lazure T, Ba N, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006;8:R51.
15. Rodrigo L. Celiac disease. World J Gastroenterol 2006;12:6585-93.
16. Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, et al. Prevalence of celiac disease among children in Finland. N Engl J Med 2003;348:2517-24.
17. Tommasini A, Not T, Kiren V, Baldas V, Santon D, Trevisiol C, et al. Mass screening for coeliac disease using anti-human transglutaminase antibody assay. Arch Dis Child 2004;89:512-5.
18. Hill ID, Dirks MH, Liptak GS, Colletti RB, Fasano A, Guandalini S, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. JPGN 2005;40:1-19.
19. Sollid LM, Thorsby E. HLA susceptibility genes in celiac disease: genetic mapping and role in pathogenesis. Gastroenterology 1993;105:910-22.
20. Spurkland A, Ingvarsson G, Falk ES, Knutsen I, Sollid LM, Thorsby E. Dermatitis herpetiformis and celiac disease are both primarily associated with the HLA-DQ (alpha 1*0501, beta 1*02) or the HLA-DQ (alpha 1*03, beta 1*0302) heterodimers. Tissue Antigens 1997;49:29-34.
21. Molberg Ø, Solheim Flaete N, Jensen T, Lundin KE, Arentz-Hansen H, Anderson OD, et al. Intestinal T-cell response to high-molecular-weight glutenins in celiac disease. Gastroenterology 2003;125:337-44.
22. Vader W, Stepniak D, Kooy Y, Mearin ML, Thompson A, Spaenij L, et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to magnitude and breadth of gluten-specific T-cell response. Prot Natl Acad Sci USA 2003;100:12390-5.
23. Koning F. Celiac disease: caught between a rock and a hard place. Gastroenterology 2005;129:1294-301.
24. Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillière's Clin Gastroenterol 1995;9:273-93.
25. Obberhuber G, Granditsch G, Vogelsang H. The histopathology of celiac disease: time for a standardization report scheme for pathologists. Eur J Gastroenterol Hepatol 1999;11:1185-94.
26. Catassi C, Fabiani E. The spectrum of celiac disease in children. Baillière's Clin Gastroenterol 1997;11:485-507.
27. van Heel DA, West J. Recent advances in coeliac disease. Gut 2006;55:1037-46.
28. Tonutti E, Visentini D, Bizzaro N, Caradonna M, Cerni L, Villalta D, et al. The role of anti-tissue transglutaminase assay for the diagnosis and monitoring of celiac disease. J Clin Pathol 2003;56:389-93.
29. Rostom A, Dube C, Cranney A, Saloojee N, Sy R, Garritty C, et al. The diagnostic accuracy of serological tests for celiac disease: a systematic review. Gastroenterology 2005;128:S38-46.
30. Brar P, Kwon GY, Egbuna II, Holleran S, Ramakrishnan R, Bhagat G, et al. Lack of correlation of degree of villous atrophy with severity of clinical presentation of celiac disease. Dig Liver Dis 2007;39:26-9.
31. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801.
32. van Meensel B, Hiele M, Hoffman I, Vermeire S, Rutgeerts P, Geboes K, et al. Diagnostic accuracy of ten second-generation (human) tissue transglutaminase autoantibody assays in celiac disease. Clin Chem 2004;50:2125-35.
33. Kaukinen K, Mäki M, Partanen J, Sievänen H, Collin P. Celiac disease without villous atrophy. Revision of criteria called for. Dig Dis Sci 2001;46:879-87.
34. Simell S, Kupila A, Hoppu S, Hekkala A, Simell T, Ståhlberg M-R, et al. Natural history of transglutaminase autoantibodies and mucosal changes in children carrying HLA-conferred celiac disease susceptibility. Scand J Gastroenterol 2005;40:1182-91.
35. Scoglio R, Di Pasquale G, Pagano G, Lucanto MC, Magazzu G, Sferlazzas C. Is intestinal biopsy always needed for diagnosis of celiac disease? Am J Gastroenterol 2003;98:1325-31.
36. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Inchingolo CD, Monardo E, et al. Endoscopic and histological findings in the duodenum of adults with celiac disease before and after changing to a gluten free diet: a 2-year prospective study. Endoscopy 2006;38:702-7.
37. Hakanen M, Luotola K, Salmi J, Laippala P, Kaukinen K, Collin P. Clinical and subclinical autoimmune thyroid disease in adult celiac disease. Dig Dis Sci 2001;46:2631-5.
38. Ventura A, Neri E, Ughi C, Leopaldi A, Citta A, Not T. Gluten-dependent diabetes-related and thyroid-related autoantibodies in patients with celiac disease. J Pediatr 2000;137:263-5.
39. Gilbert JA, Kalled SL, Moorhead J, Hess DM, Rennert P, Li Z, et al. Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology 2006;147:4561-8.
40. Cellier C, Delabesse E, Helmer C, Patey N, Matuchansky C, Jabri B, Macintyre E, Cerf-Bensussan N, Brousse N. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet 2000;356:203-8.
41. Cerf-Bensussan N, Brousse N, Cellier C. From hyperplasia to cell lymphoma. Gut 2002;51:304-5.
42. Mackay F, Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006;18:284-9.
43. Shivakumar L, Ansell S. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. Clin Lymphoma Myeloma 2006;7:106-8.